FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Novo Nordisk and Eli Lilly are significantly lowering prices of their blockbuster obesity drugs Wegovy and Mounjaro in China, a move aimed at expanding access in one of the world’s fastest-growing weight-loss markets and staying competitive amid rising local rivalry.
Novo Nordisk confirmed it has adjusted Wegovy prices in China, though it did not disclose specific figures. However, Chinese financial media outlet Yicai reported that list prices for the two highest doses of Wegovy were reduced by as much as 48% in certain provinces. According to the report, monthly prices dropped to about 987 yuan ($141) and 1,284 yuan, based on information from local procurement authorities. The reductions were reportedly implemented in southwestern provinces including Yunnan and Sichuan.
In a statement to Reuters, Novo Nordisk said the pricing adjustment is intended to help reduce the treatment burden for patients and improve quality of life. The Danish drugmaker is aggressively expanding its footprint in emerging markets as demand for obesity treatments accelerates globally.
Eli Lilly has not officially commented, but signs of price cuts for Mounjaro are already emerging. A hospital in Nanjing announced via its WeChat account that prices would fall starting January 1. Meanwhile, Meituan’s healthcare platform listed a 10mg Mounjaro injector pen at an estimated price of around 445 yuan, sharply down from about 2,180 yuan, signaling a substantial reduction.
China represents a massive growth opportunity, with more than 65% of its 1.4 billion population projected to be overweight or obese by 2030. However, competition is intensifying. Both Novo Nordisk and Eli Lilly face pressure from domestic drugmakers such as Innovent Biologics, CSPC Pharmaceutical Group, and Hangzhou Jiuyuan Genetic Biopharmaceutical, which are developing rival weight-loss drugs.
Further competition looms as Novo’s patent on semaglutide, Wegovy’s active ingredient, is set to expire in China in 2026. The latest price cuts mirror similar moves in India and the United States, underscoring a broader shift toward affordability and cash-paying consumers in the global obesity drug market.
